- Home
- PHVS vs CLDX Comparison
PHVS vs CLDX Comparison
Compare PHVS & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHVS | CLDX |
|---|---|---|
| Founded | 2015 | N/A |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.1B |
| IPO Year | 2020 | 1995 |
Fundamental Metrics
Financial Performance| Metric | PHVS | CLDX |
|---|---|---|
| Price | $27.65 | $33.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 10 |
| Target Price | $41.82 | ★ $46.60 |
| AVG Volume (30 Days) | 204.7K | ★ 1.1M |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,743,000.00 |
| Revenue This Year | N/A | $111.39 |
| Revenue Next Year | N/A | $235.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 87.78 |
| 52 Week Low | $15.51 | $17.87 |
| 52 Week High | $30.24 | $35.83 |
Technical Indicators
Market Signals| Indicator | PHVS | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 49.84 | 57.37 |
| Support Level | $24.55 | $28.30 |
| Resistance Level | $28.35 | $34.52 |
| Average True Range (ATR) | 1.30 | 1.24 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 46.28 | 54.05 |
Price Performance
Historical ComparisonAbout PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.